PUS1 and breast cancer: Accordingly, high PUS1 mRNA levels predict poor overall survival and relapse-free survival in METERBRIC (HR=1.264, P <0.0001; HR=1.381, P <0.0001) and GSE1456 datasets (HR=4.295, P <0.0001; HR=3.566, P <0.0001) as well as adverse disease specific survival in GSE3494 dataset (HR=3.144, P <0.0001), showing that PUS1 is an unfavorable biomarker for breast cancer (Figures 2C–E).